SAB Biotherapeutics (SABS) announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes clinical trial. SAB-142 is in development as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach to treat stage 3 T1D by delaying the progression of disease. The SAFEGUARD trial is currently enrolling additional study participants at multiple centers around the globe, including the U.S., Australia, and New Zealand, with European sites joining soon. The first patient in SAFEGUARD was dosed at The Royal Melbourne Hospital in Australia by Professor John Wentworth and team.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint
- Eleven new option listings and two option delistings on December 8th
- SAB Biotherapeutics to present data on progress in development of SAB-142
- SAB Biotherapeutics Reports Positive Q3 2025 Earnings
- Sab Biotherapeutics, Inc. (SABS) Q3 Earnings Cheat Sheet